

MORTALITY PROGNOSTICATING PERFORMANCE COMPARISONS OF C-REACTIVE PROTEIN AND ITS RATIO TO ALBUMIN DURING FIRST WEEK OF ADMISSION IN SEPTIC CRITICALLY ILL PATIENTS

“Moh’d Nour” Mahmoud Bani Younes, Ph, Mohammed Ali Obeidat, MD, Mohammad Ahmad Bani Hani, MD, Kais Yazid Ghanma, MD, Ann Farah Nimri, MD, Basel Naem Al-Rawashdeh, MD, Areej Mohammed Almanaseer Ph and Maha Kareem Al Amr, MD

King Hussein Medical Hospital, Jordanian Royal Medical Services, Amman, Jordan

ARTICLE INFO

Article History:

Received 15th February, 2019

Received in revised form 7th

March, 2019

Accepted 13th April, 2019

Published online 28th May, 2019

Key words:

Critical ill patients, C-reactive protein, Dynamic changes, Hypoalbuminemia, Mortality.

ABSTRACT

Background: C-reactive protein (CRP) and albumin level (ALB) are acute phase reactants and are used in many studies as mortality prognosticators.

Objective: The aim of this study is to evaluate the prediction performance differences between CRP at admission (CRP₁) and its ratio to ALB (CRP:ALB₁), CRP 1 week after admission (CRP₂) and its ratio to ALB (CRP:ALB₂), and percentage changes of CRP to ALB ratio during first week of ICU admission (% Δ CRP:ALB ratio) for prediction of early ICU mortality (≤14 days of admission), late ICU admission (>14 days of admission), and overall 28-ICU mortality in critically ill patients with septic shock who were taking norepinephrine.

Methods: This single-center retrospective study conducted in the department of adult Intensive Care Unit (ICU) by examining the medical records between April 2017 to Sep 2018. All patient's variables were analyzed using independent samples T-test, χ^2 test, or Mann-Whitney U test.

Result: The mean overall age was 58.37±9.96 years, and 112 subjects (68.71%) were male. The early, late, and overall 28-day ICU mortality rate were 16 patients (9.82%), 48 patients (29.45%), and 64 patients (39.26%), respectively. The CRP₂, CRP:ALB₂, and %ΔCRP:ALB were significantly higher in nonsurvivors than survivors. %ΔCRP:ALB shows the highest performance for prediction of late (66.00%) and overall 28-day mortality (81.40%) in compared with other tested prognosticators.

Conclusion: %ΔCRP:ALB is an effective, realistic, dynamic, reliable, and discriminative prognosticator with high performance, specificity, positive predictive value, and accuracy when compared with other relative tested prognosticators for prediction of late and 28-day but not early ICU mortality.

Copyright © 2019 “Moh’d Nour” Mahmoud Bani Younes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Globally, sepsis is defined as systemic inflammatory response syndrome (SIRS) with evidence of infection which poses substantial clinical, financial, logistical challenges, and chronic inflammatory and nutritional negative impacts.¹⁻³ This physiological response to systemic inflammation onset positive-phase reactants synthesis like CRP in preference of negative-phase reactants like ALB. CRP is a useful positive acute-phase reactant marker that can predict morbidity and mortality among critically ill patients and may be used to predict the prognosis of septic patients.⁴⁻⁹ The prognostic roles of CRP and ALB can be explained by their direct and indirect relationships regarding ALB synthesis rate, ALB catabolic rate, ALB transcapillary escaping rate (TER), and malnutrition status in which the clinical usefulness of CRP: Ratio are proved in many retrospective and prospective studies.¹⁰⁻²²

Based on these interrelated correlations and the dynamic instability status of the critically ill patients, we proposed that the prognosticator efficacy of CRP: ALB ratio may be increased if we assessed the changes of CRP:ALB over the first week of ICU admission because this mortality predictors

is a reliable, affordable, and clinically applicable that may help prognosticate the survival of these patients and would subsequently force the care of septic critically ill patients and assist in the course of effective treatment. Our objective was to test the hypothesis that % Δ CRP:ALB ratio have a higher mortality prognostic performance than the other objective analogue independent prognostic indicators of CRP₁, CRP₂, CRP:ALB₁, and CRP:ALB₂ in prediction the primary outcome of overall 28-day mortality, and the secondary outcomes of early mortality (≤ 14 days), late mortality (>14 days), and overall hospital and ICU length of stay (LOS) in septic critically ill patients who are taking norepinephrine as a vasopressor taking into consideration the dynamic pattern of these cohort patients. This study also aimed to determine the optimal cut-off point of the five tested prognosticators and to examine these five mortality predictors as a novel prognostic factors.

MATERIALS AND METHODS

This retrospective study was conducted in the department of adult Intensive Care Unit (ICU) of King Hussein Medical

*Corresponding author: “Moh’d Nour” Mahmoud Bani Younes

King Hussein Medical Hospital, Jordanian Royal Medical Services, Amman, Jordan

Center (KHMC), Royal Medical Services, Jordan. This study was approved by our institutional review board, and a requirement for consent was waived owing to its retrospective design. Patients were included if the study patients were admitted to our adult ICU via the emergency department (ED) or via other hospital wards with any medical or surgical problem between April 2017 to Sep 2018. Flow chart of critically ill patient's selection and data collection process is fully illustrated in **Figure 1**. All patient continuous variables were expressed as mean \pm standard deviation by using the independent samples T-test while categorical and ordinal variables were expressed as numbers with percentages by using the χ^2 test or as median (interquartile range) by using the Mann-Whitney U test, respectively. Analysis values were compared for the two tested groups (survivors vs. non-survivors) and the non-survival group was further analysed after being divided into 2 subgroups, early (≤ 14 days) and late (>14 days) mortality. A receiver operating characteristic (ROC) curve followed by sensitivity analysis was used to determine the area under the ROC curves (AUROCs), predictive performances, and the optimal cut-off values for the five tested prognosticators. Youden's indices, sensitivities, specificities, positive and negative predictive values, and accuracy indices were also calculated. Statistical analyses were performed using IBM SPSS ver. 25 (IBM Corp., Armonk, NY, USA) and P-values ≤ 0.05 were considered statistically significant.

RESULT

The mean overall age was 58.37 \pm 9.96 years, and 112 subjects (68.71%) were male. The early, late, and overall 28-day ICU mortality rate were 16 patients (9.82%), 48 patients (29.45%), and 64 patients (39.26%), respectively. Pre-ICU, ICU, and overall hospital stay days were significantly higher in non-survivors than survivors (7.42 \pm 4.57 days, 17.30 \pm 4.14 days, and 24.72 \pm 1.98 days vs 2.23 \pm 1.06 days, 9.23 \pm 1.06 days, and 11.46 \pm 2.12 days, respectively). There were insignificant differences between the survivors and nonsurvivors regarding average child-Pugh score, average Glasgow coma scale (GSC), and average norepinephrine infusion rate. Despite CRP₁ was insignificantly higher in nonsurvivors than survivors (8.29 \pm 3.77 mg/dl vs 7.69 \pm 2.54 mg/dl), the CRP:ALB₁ was significantly higher (3.21 \pm 1.79 vs 2.84 \pm 1.21) due to significantly higher ALB₁ in survivors in compared with nonsurvivors (2.79 \pm 0.20 g/dl vs was 2.74 \pm 0.29 g/dl). The CRP₂, CRP:ALB₂, and % Δ CRP:ALB were significantly higher in nonsurvivors than survivors (49.80 \pm 16.05 mg/dl, 33.00 \pm 19.77, and 1111.16 \pm 824.86% vs 22.96 \pm 8.18 mg/dl, 8.29 \pm 4.70, and 202.88 \pm 119.13%, respectively) while ALB₂ was significantly higher in survivors than nonsurvivors (2.98 \pm 0.41 g/dl vs 1.79 \pm 0.52 g/dl). Regarding nutritional indices, only protein density (PD) and percentage of protein calorie from total calorie (%PC_{TC}) were significantly higher in survivors than nonsurvivors (3.72 \pm 0.74 g/100 Cal and 10.84 \pm 2.74% vs 3.50 \pm 0.36 g/100 Cal and 9.45 \pm 0.99%, respectively) while total calorie (TC) was insignificantly higher in survivors than nonsurvivors (1357.56 \pm 270.23 Cal/day vs 1280.54 \pm 243.32 Cal/day). Demographics, anthropometrics, assessment scores, nutritional variables, stay days, and follow-up tested mortality predictors comparison data of the study's critically ill patients are fully summarised in Table 1. Table 2 shows the optimal cut-off point, sensitivity (TPR), specificity (TNR), Youden's index (YI), positive and negative predictive values (PPV and NPV), negative likelihood

ratio (NLR), and accuracy index (AI) of the five tested prognosticators among the three stratified mortalities. The best cut-off values for CRP₁, CRP:ALB₁, CRP₂, CRP:ALB₂, and % Δ CRP:ALB in our study among mechanically ventilated critically ill patients were (12.55 mg/dl, 18.91 mg/dl, 5.29:1, 7.87:1, 61.25%, respectively) for overall 28-day ICU mortality, (13.70 mg/dl, 27.18 mg/dl, 5.91:1, 12.06:1, and 86.52%, respectively) for early ICU mortality, and (10.63 mg/dl, 17.71 mg/dl, 4.29:1, 6.85:1, and 48.89%, respectively) for late mortality. The AUROCs of the five tested prognosticators in this study were significantly greater for % Δ CRP:ALB than CRP₂, CRP:ALB₂, CRP₁, and CRP:ALB₁ (0.971, 0.941, 0.925, 0.701, and 0.701, respectively). The ROC curve analyses of the five tested prognosticators for early, late, and overall 28-day ICU mortality are fully shown in **Fig 2-4**.

DISCUSSION

The present study included septic mechanically ventilated critically ill patients who were taking norepinephrine as a vasopressor at an overall average rate of 9.53 \pm 1.79 mcg/min. To the best of our knowledge, this is the first study that compare five prognosticators of CRP and their ratios and changes over first week of ICU admission to prognosticate early, late, and overall ICU mortality. In the context of ever-shrinking resources, early stratification with affordable, valid, reliable, and discriminative predictive tools are critically needed in this unstable, high acuity, and high uncertainty status of the septic critically ill to avoid any potential delay or under-triaging while appropriately assigning a higher priority to sicker patients.²³⁻²⁸ The greater significant ALB₂ in survivors in compared with nonsurvivors (2.98 \pm 0.41 g/dl vs 1.79 \pm 0.52 g/dl) may be attributed to multifactorial reasons included; significant lower CRP₂ (22.96 \pm 8.18 mg/dl vs 49.80 \pm 16.05 mg/dl), significantly higher PD and %PC_{TC} (3.72 \pm 0.74 g/100 Cal and 10.84 \pm 2.74% vs 3.50 \pm 0.36 g/100 Cal and 9.45 \pm 0.99%, respectively), and significantly higher human albumin dose (18.89 \pm 3.159 g/day vs 14.06 \pm 6.09 g/day). After careful analysis of the data, % Δ CRP:ALB shows higher performance, specificity, positive predictive value, and accuracy (81.40%, 97.00%, 94.79%, and 92.05%, respectively) for 28-day ICU mortality than CRP₂, CRP:ALB₂, CRP₁, and CRP:ALB₁. Also, % Δ CRP:ALB still shows the highest performance in compared with CRP₂, CRP:ALB₂, CRP₁, and CRP:ALB₁ (66.00% vs 62.20%, 55.70%, 60.90%, and 30.80%) for late mortality. In case of early mortality, CRP₂ has the highest performance in compared with % Δ CRP:ALB, CRP:ALB₂, CRP₁, and CRP:ALB₁ (98.00% vs 87.70%, 93.20%, 67.30%, and 67.30%, respectively), possibly due to H.ALB administration that underestimate the performance of CRP:ALB as early mortality prognosticators. In summary, % Δ CRP:ALB is an effective, realistic, dynamic, reliable, and discriminative prognosticator with high performance, specificity, positive predictive value, and accuracy when compared with other relative prognosticators like; CRP₂, CRP:ALB₂, CRP₁, and CRP:ALB₁ for prediction of late and 28-day ICU mortality while in case of early ICU mortality, CRP change and ratio have a lower performance than CRP alone due to underestimation effects of H.ALB in septic mechanically ventilated critically ill patients who are taking norepinephrine. This study is limited by its retrospective design, confounder effect of H.ALB, and using single-centre data, including only septic mechanically ventilated ICU patients. Nonetheless, our centre is an experienced and high-volume unit, so our data may be useful in other centres. A

larger, multisite, and prospective study is needed to control for multiple confounders and to clarify the mortality performance of the five tested prognosticators for mortality risk early stratification of hospitalized patients including critically ill cohorts.




Fig 1 Flow chart of critically ill patient's selection and data collection process.
 Apr: April. CRP: C-reactive protein. PD: Protein density.
 Sep: September. ALB: Albumin. TC: Total calorie.
 ICU: Intensive Care Unit. N: Number of studied critically ill patients.




Fig 2 Receiver operating characteristic (ROC) curve analysis of C-reactive protein at and 1 week after ICU admission (CRP1 and CRP2, respectively), CRP to albumin ratio at and 1 week after ICU admission (CRP:ALB1 and CRP:ALB2, respectively), and the changes of CRP:ALB ratio during first week of ICU admission (% Δ CRP:ALB) to determine the area under the curve of ROC (AUC) of each prognosticator for overall 28-day ICU mortality. The AUC of % Δ CRP:ALB (0.971, 95% CI, 0.961-0.982) was significantly higher than in CRP2 (0.941, 95% CI, 0.917-0.976) followed by CRP:ALB2 (0.925, 95% CI, 0.888-0.962) and CRP1 or CRP:ALB1 (0.773, 95% CI, 0.701-0.844).

Table 1 Baseline and follow-up data of the comparative studied critically ill patient

Variables	Total(N=163)	Survivors(N=99)	Non-survivors (N=64)		P-Value	
			Early Mortality(≤14 days) (N=16)	Late Mortality (>14 days) (N=48)		
Age (Yrs)	58.37±9.96	58.55±9.948	62.31±11.12	58.09±10.053	0.917 NS	
Gender			Male	45 (70.31%)	34 (70.83%)	0.796 NS
			Female	19 (29.69%)	14 (29.17%)	
Day(s) Pre-ICU admission (day(s))	4.27±3.91	2.23±1.06	13.31±5.89	7.42±4.57	0.000 S	
ICU Stay day(s)	12.40±4.79	9.23±1.06	10.56±1.97	17.30±4.14	0.000 S	
Hospital Stay day(s)	16.67±6.81	11.46±2.12	23.87±3.93	24.72±1.98	0.003 S	
BW ₁ (Kg)	74.17±10.24	74.63±10.06	69.44±9.34	73.45±10.56	0.609 NS	
BMI ₁ (Kg/m ²)	25.92±4.00	26.19±3.85	24.11±4.28	25.50±4.22	0.311 NS	
Child-Pugh Score _{avg} (5-15)	6 (6-8)	6 (6-8)	6 (6-7)	6 (6-7)	0.088 NS	
GCS _{avg} (3-15)	12 (12-13)	12 (12-13)	12 (12-13)	12 (12-13)	0.341 NS	
Human Albumin Dose _{avg} (g/day)			9.38±6.80	14.06±6.09	0.02 (S)	
			2.77±0.25	2.79±0.20		
ALB ₁ (g/dl)	2.77±0.25	2.79±0.20	2.82±0.29	2.74±0.29	0.049 (S)	
CRP ₁ (mg/dl)	7.94±3.12	7.69±2.54	7.35±3.63	8.29±3.77	0.053 (NS)	
CRP:ALB ₁ (X:1)	2.99±1.49	2.84±1.21	2.76±1.58	3.21±1.79	0.032 (S)	
ALB ₂ (g/dl)	2.48±0.74	2.98±0.41	1.53±0.44	1.79±0.52	0.000 (S)	
CRP ₂ (mg/dl)	34.16±17.94	22.96±8.18	59.51±16.31	49.80±16.05	0.000 (S)	
CRP:ALB ₂ (X:1)	18.60±17.99	8.29±4.70	44.26±21.16	33.00±19.77	0.000 (S)	
%ΔCRP:ALB	581.80%±701.04%	202.88%±119.13%	1806.02%±895.37%	1111.16%±824.86%	0.000 (S)	
TC _{avg} (Cal/kg/day)	19.33±3.41	19.79±3.56	17.58±3.63	18.62±3.06	0.208 NS	
TC _{avg} (Cal/day)	1327.32±261.96	1357.56±270.23	1181.86±269.47	1280.54±243.32	0.581 NS	
PD _{avg} (g/100Cal/day)	3.64±0.63	3.72±0.74	3.46±0.42	3.50±0.36	0.002 S	
% PC _{TC} _{avg} (%)	10.29%±2.32%	10.84%±2.74%	9.00%±0.94%	9.45%±0.99%	0.000 S	
Norepinephrine Rate _{avg} (mcg/min)	9.53±1.79	9.27±1.68	9.94±2.49	9.94±1.89	0.724 NS	
28-day ICU Survival			99 (60.74%)	9.94±1.67		
Overall Mortality			64 (39.26%)		0.000 S	
Mortality			Early Mortality (≤14 days)	16 (9.82%)		
			Late Mortality (>14 days)	48 (29.45%)		

Values are presented as mean ± SD, median (range), or number (%).
 N: Number of study's critically ill patients.
 ICU: Intensive care unit.
 1: Baseline at ICU admission.
 2: 1 week after ICU admission.



Δ: Changes.
 Avg: Average.
 BMI: Body mass index.
 BW: Body weight.
 g: Gram.
 S: Significant (P-Value <0.05).
 NS: Non-significant (P-Value >0.05).
 mcg: microgram.
 Cal: Kcal.
 TC: Total calories.
 PD: Protein density.
 CRP: C-reactive protein.
 GCS: Glasgow coma scale.
 ALB: Albumin level.

Table 2 Sensitivity, specificity, positive and negative predictive values, youden’s and accuracy indices of the five tested prognosticators for overall 28-day ICU mortality, early and late ICU mortality.

Prognostic Indicator	Cutoff Values	TPR	FPR	YI	TNR	PPV	NPV	NLR	AI	
Overall 28-day mortality	CRP ₁	12.55	75.00%	27.30%	47.70%	72.70%	63.98%	81.81%	34.39%	73.60%
	CRP ₂	18.91	90.60%	16.20%	74.40%	83.80%	78.33%	93.24%	11.22%	86.47%
	CRP: ALB ₁	5.29	75.00%	27.30%	47.70%	72.70%	63.98%	81.81%	34.39%	73.60%
	CRP: ALB ₂	7.87	90.60%	22.20%	68.40%	77.80%	72.51%	92.76%	12.08%	82.83%
	%Δ CRP:ALB	61.25%	84.40%	3.00%	81.40%	97.00%	94.79%	90.58%	16.08%	92.05%
Early mortality (≤14 days)	CRP ₁	13.70	100.00%	32.70%	67.30%	67.30%	66.41%	100.00%	0.00%	80.14%
	CRP ₂	27.18	100.00%	2.00%	98.00%	98.00%	97.00%	100.00%	0.00%	98.79%
	CRP: ALB ₁	5.91	100.00%	32.70%	67.30%	67.30%	66.41%	100.00%	0.00%	80.14%
	CRP: ALB ₂	12.06	100.00%	6.80%	93.20%	93.20%	90.48%	100.00%	0.00%	95.87%
	%Δ CRP:ALB	86.52%	93.80%	6.10%	87.70%	93.90%	90.86%	95.91%	6.60%	93.86%
Late mortality (>14 days)	CRP ₁	10.63	91.70%	60.90%	30.80%	39.10%	49.33%	87.93%	21.23%	59.75%
	CRP ₂	17.71	97.90%	35.70%	62.20%	64.30%	63.94%	97.93%	3.27%	77.49%
	CRP: ALB ₁	4.29	91.70%	60.90%	30.80%	39.10%	49.33%	87.93%	21.23%	59.75%
	CRP: ALB ₂	6.85	100.00%	44.30%	55.70%	55.70%	59.34%	100.00%	0.00%	73.09%
	%Δ CRP:ALB	48.89%	93.80%	27.80%	66.00%	72.20%	68.57%	94.74%	8.59%	80.68%

CRP₁: C-reactive protein at ICU admission.
 CRP₂: C-reactive protein after 1 week of ICU admission.
 CRP:ALB₁: C-reactive protein to albumin level ratio at ICU admission.
 CRP:ALB₂: C-reactive protein to albumin level ratio 1 week of ICU admission.
 %ΔCRP:ALB: Percentage changes of CRP:ALB during 1 week of admission.
 TPR: True positive rate (sensitivity)
 FPR: False positive rate.

TNR: True negative rate (Specificity).
 PPV: Positive predictive value.
 NPV: Negative predictive value.
 NLR: Negative likelihood ratio.
 AI: Accuracy index.
 YI: Youden’s index.



References

- Members of the American College of Chest Physicians / Society of Critical Care Medicine Consensus Conference Committee: Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis. *Crit Care Med.* 1992; 20:864-874.
- Sibbald W, Doig G, Inman K. Sepsis, SIRS and Infection. *Intensive Care Med.* 1995; 21:299-301.

- Dysfunction with Mortality in Emergency Department Patients with Suspected Infection. *Ann Emerg Med.* 2006; 48:583-590.
- Vladimirova SG, Tarasova LN, Sokol'skaia O, Cherepanova VV. [C-reactive protein as a marker of theseverity of an infectious process in acute myeloid leukemia patients with neutropenia]. *Terapevticheskiiarkhiv.* 2013; 85(11):34-40.
- Gradel KO, Thomsen RW, Lundbye-Christensen S, Nielsen H, Schonheyder HC. Baseline C-reactive protein level as a predictor of mortality in bacteraemia patients: a population-based cohort study. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases.* 2011; 17(4):627-32.
- Juvela S, Kuhmonen J, Siironen J. C-reactive protein as predictor for poor outcome after aneurysmal subarachnoid haemorrhage. *Actaneurochirurgica.* 2012; 154(3):397-404.
- Ho KM, Lee KY, Dobb GJ, Webb SA. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a prospective cohort study. *Intensive care medicine.* 2008; 34(3):481-7.
- Artero A, Zaragoza R, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. Prognostic factors of mortality in patients with community-acquired bloodstream infection with severe sepsis and septic shock. *Journal of critical care.* 2010; 25(2):276-81.
- Devran, O.; Karakurt, Z.; Adiguzel, N.; Gungor, G.; Mocin, O.Y.; Balci, M.K.; Celik, E.; Salturk, C.; Takir, H.B.; Kargin, F.; et al. C-reactive protein as a predictor of mortality in patients affected with severe sepsis in intensive care unit. *Multidiscip. Respir. Med.* 2012, 7, 47.
- Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. *PloS one.* 2013; 8(3):e59321.
- Xie Q, Zhou Y, Xu Z, Yang Y, Kuang D, You H, et al. The ratio of CRP to prealbumin levels predict

- mortality in patients with hospital-acquired acute kidney injury. *BMC nephrology*. 2011; 12:30.
12. Dominguez de Villota, E.; Mosquera, J.M.; Rubio, J.J.; Galdos, P.; DiezBalda, V.; de la Serna, J.L.; Tomas, M.I. Association of a low serum albumin with infection and increased mortality in critically ill patients. *Intensive Care Med*. **1980**, 7, 19–22.
 13. Kim MH, Ahn JY, Song JE, et al. The C-reactive protein/albumin ratio as an independent predictor of mortality in patients with severe sepsis or septic shock treated with early goal-directed therapy. *PLoS One* 2015;10:e0132109.
 14. Quispe, E.A.; Li, X.M.; Yi, H. Comparison and relationship of thyroid hormones, il-6, il-10 and albumin as mortality predictors in case-mix critically ill patients. *Cytokine* **2016**, 81, 94–100.
 15. Pova, P. C-reactive protein: A valuable marker of sepsis. *Intensive Care Med*. **2002**, 28, 235–243.
 16. Carriere, I.; Dupuy, A.M.; Lacroux, A.; Cristol, J.P.; Delcourt, C. Pathologies Oculaires Liees a l'Age Study Group. Biomarkers of inflammation and malnutrition associated with early death in healthy elderly people. *J. Am. Geriatr. Soc.* **2008**, 56, 840–846.
 17. Ranzani, O.T.; Zampieri, F.G.; Forte, D.N.; Azevedo, L.C.; Park, M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. *PLoS ONE* **2013**, 8, e59321.
 18. Arima, K.; Yamashita, Y.I.; Hashimoto, D.; Nakagawa, S.; Umezaki, N.; Yamao, T.; Tsukamoto, M.; Kitano, Y.; Yamamura, K.; Miyata, T.; et al. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. *Am. J. Surg.* **2017**.
 19. Sun, F.; Ge, X.; Liu, Z.; Du, S.; Ai, S.; Guan, W. Postoperative C-reactive protein/albumin ratio as a novel predictor for short-term complications following gastrectomy of gastric cancer. *World J. Surg. Oncol.* **2017**, 15,191.
 20. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004;350:1387-97.
 21. Sullivan DH, Roberson PK, Bopp MM. Hypoalbuminemia 3 months after hospital discharge: significance for long-term survival. *J Am Geriatr Soc* 2005;53:1222-6.
 22. Kim MH, Ahn JY, Song JE, et al. The C-reactive protein/albumin ratio as an independent predictor of mortality in patients with severe sepsis or septic shock treated with early goal-directed therapy. *PLoS One* 2015;10:e0132109.
 23. Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. *Postgrad Med* 2011;123:114-9.
 24. Hannan JL, Radwany SM, Albanese T. In-hospital mortality in patients older than 60 years with very low albumin levels. *J Pain Symptom Manage* 2012;43:631-7.
 25. Heimburger O, Qureshi AR, Blaner WS, Berglund L, Stenvinkel P. Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. *Am J Kidney Dis.* 2000;36:1213–25.
 26. Quispe, E.A.; Li, X.M.; Yi, H. Comparison and relationship of thyroid hormones, il-6, il-10 and albumin as mortality predictors in case-mix critically ill patients. *Cytokine* **2016**, 81, 94–100.
 27. Pova, P. C-reactive protein: A valuable marker of sepsis. *Intensive Care Med*. **2002**, 28, 235–243.
 28. Dominguez de Villota, E.; Mosquera, J.M.; Rubio, J.J.; Galdos, P.; Diez Balda, V.; de la Serna, J.L.; Tomas, M.I. Association of a low serum albumin with infection and increased mortality in critically ill patients. *Intensive Care Med*. **1980**, 7, 19–22.

How to cite this article:

“Moh'd Nur” Mahmoud Bani Younes *et al* (2019) 'Mortality Prognosticating Performance Comparisons of c-Reactive Protein and its Ratio to Albumin During First week of Admission in Septic Critically ill Patients', *International Journal of Current Medical And Pharmaceutical Research*, 05(05), pp 4184-4188.
